June 26, 2025
CHICAGO — Once-weekly semaglutide improved glycemia and reduced weight without increasing hypoglycemia in adults with type 1 diabetes (T1D) and obesity, new research presented at the […]
June 25, 2025
Canada can build successful diabetes prevention and remission programs across the country by learning from England, a Quebec-based team of clinician-scientists and other experts suggested. England’s […]
June 25, 2025
LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to […]
June 24, 2025
CHICAGO — Use of the GLP-1 receptor agonist semaglutide improved walking capability in patients with peripheral arterial disease (PAD) and type 2 diabetes (T2D), regardless of […]
June 24, 2025
CHICAGO — Combined use of semaglutide with an investigational monoclonal antibody called bimagrumab produced significant fat mass loss while preserving lean mass, results from the phase […]
June 23, 2025
Insulin requirements fluctuated significantly throughout the menstrual cycle without a consistent pattern, prompting a substantial proportion of premenopausal women with type 1 diabetes (T1D) to manually […]
June 23, 2025
CHICAGO — CagriSema, a new weekly injection from Novo Nordisk combining the amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide, significantly reduced weight and improved […]
June 22, 2025
CHICAGO — The investigational once-weekly basal insulin analog efsitora alfa lowered A1c as effectively as daily basal insulins in people with type 2 diabetes (T2D) who […]
June 22, 2025
TOPLINE: Behavioral support for first-time users of a continuous glucose monitoring (CGM) device showed no significant difference in reduction of A1c levels compared with CGM alone […]